ESLA Stock Price, Chart, Stats & News
Estrella Immunopharma, Inc. (ESLA) does not currently pay a dividend.
ESLA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.01% |
ROA | -411.19% |
ROE | 185.77% |
D/E | – |
Interest coverage ratio | – |
ESLA valuation
P/E | – |
P/S | – |
P/B | -3.85x |
P/CF | -22.33x |
P/FCF | -25.09x |
P/OCF | -22.33x |
PEG | -0.56x |
EV multiple | -3.54x |
About
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103.
Similar securities
Based on sector and market capitalization
